Abbott has achieved milestones in diabetes and cancer treatments, which may indicate a positive growth story for the company. However, the company's share price has been weak, prompting some to consider it a potential bargain stock. Additionally, Abbott faces scrutiny from the FDA, which may impact its overall performance and growth prospects.